Vinflunine: A novel antitubulin agent in solid malignancies

Expert Opinion on Investigational Drugs

Volumn 14, Issue 10, 2005, Pages 1259-1267

  Bennouna, Jaafar ^a   Campone, Mario ^a   Delord, Jean Pierre ^a   Pinel, Marie Claire ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Bladder; Breast; Carcinoma; Lung; Vinflunine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CREMOPHOR; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LAXATIVE; LONAFARNIB; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM; POLYSORBATE 80; TAXANE DERIVATIVE; TRASTUZUMAB; TUBULIN; VINFLUNINE;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; APOPTOSIS; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL GROWTH; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GENE TARGETING; GROWTH INHIBITION; HUMAN; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MICROTUBULE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; SEPTIC SHOCK; SOLID TUMOR; STOMATITIS; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; TUMOR CELL; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; NEOPLASMS; TUBULIN MODULATORS; VINBLASTINE;

EID: 27144513351     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.10.1259     Document Type: Article

References (39)

1. JACQUESY JC, FAHY J: Cancer: superacid generation of new antitumor agents. In: Biomedical Chemistry: applying chemical principles to the understanding and treatment of disease. PF Torrence (Ed.), John Wiley & Sons Inc. (2000).
2. KRUCZYNSKI A, HILL BT: Vinflunine, the latest vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit. Rev. Oncol. Hematol. (2001) 40(2):159-173.
3. KRUCZYNSKI A, BARRET JM, ETIEVANT C et al.: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated vinca alkaloid. Biochem. Phamacol. (1998) 55:635-648.
4. LOBERT S, INGRAM JW, HILL B et al.: A comparison of thermodynamic parameters for vinorelbine and vinflunine induced tubulin self-association by sedimentation velocity. Mol. Pharmacol. (1998) 53:908-915.
5. NGAN V, JORDAN MA, WILSON L, HILL BT: Vinflunine and vinorelbine, novel vinca alkaloids that act by modulation of microtubule dynamic instability and treadmilling. Clin. Cancer. Res. (1999) 5:432 (Abstract 639).
6. NGAN V, BELLMAN K, PANDA D et al.: Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. (2000) 60:5045-5051.
7. HOLWELL SE, HILL B T, BIBBY M C: Anti-vascular effects of vinflunine in the mac 15a transplantable adenocarcinoma model. Br. J. Cancer (2001) 84:290-295.
8. BARRET J-M, ETIEVANT C, HILL BT: In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anti-cancer drugs. Cancer Chemother. Pharmacol. (2000) 45:471-476.
9. ETIEVANT C, BARRET JM, CABROL N et al.: Synergistic effects of the farnesyltransferase inhibitor SCH-66336 and novel vinca alkaloids in A549 non-small cell lung cancer cells in vitro. Proc. Am. Cancer Res. (2003) 9:116 (Abstract A269).
10. SIMONTHSENS C, KORST AE, DE POOTER CM et al.: Vinflunine and radiation: a promising radiosensitizing combination? Proc. Am. Assoc. Cancer Res. (2004) 45:6-12 (Abstract 5606).
11. KRUCZYNSKI A, COLPAERT F, TARAYRE JP et al.: Preclinical in vivo antitumour activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother. Pharmacol. (1998) 41:437-447.
12. KRUCZYNSKI A, RICOME C, ASTRUC J et al.: Marked antitumour activity of vinflunine, a new fluorinated vinca-alkaloid, in murine and human experimental tumors. Ann. Oncol. (1998) 9(2):38.
13. HILL B, FIEBIG H, WAUD WR et al.: Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur. J. Cancer (1999) 35(3):512-520.
14. KRUCZYNSKI A, ASTRUC J, RICOME C et al.: Definite antitumour activity of vinflunine, a novel fluorinated vinca alkaloid, against human tumour xenografts. Contrib. Oncol. Basel, Karger (1999) 54:369-378.
15. BONFIL RD, RUSSO DM, BINDA MM et al.: Higher antitumor activity of vinflunine than vinorelbine against an orthoptic murine model of transitional cell carcinoma of the bladder. Urol. Oncol. (2002) 7:159-166.
16. ETIEVANT C, BARRET JM, KRUCZYNSKI A et al.: Vinflunine (20′, 20′-difluoro-3′,4′-dihydrovinorelbine) a novel vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Investig. New Drugs (1998) 16:3-17.
17. ETIÉVANT C, KRUCZYNSKI A, BARRET JM et al.: Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother. Pharmacol. (2001) 48(1):62-70.
18. FOCAN CNJ, VAN HEUGEN JC, KREUTZ F et al.: Vinflunine metabolism and disposition in cancer patients. Proc. Am. Soc. Clin. Oncol. (2002) 21:495 (Abstract).
19. ZORZA G, JOHNSON P, JUDSON I et al.: A Phase I pharmacokinetic study of vinflunine given on days 1 and 8 every 3 weeks. Proc. Am. Soc. Clin. Oncol. (2001) 20:2070 (Abstract).
20. PUOZZO C, VERMORKEN JB, BAUER J et al.: A Phase I pharmacokinetic study of vinflunine given on a weekly schedule. Proc. Am. Soc. Clin. Oncol. (2001) 20:2107 (Abstract).
21. BENNOUNA J, FUMOLEAU P, ARMAND JP et al.: Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumors. Ann. Oncol. (2003) 14:630-637.
22. DELORD JP, STUPP R, PINEL MC et al.: Phase I study of vinflunine given as a 10 minute intravenous (i.v.) infusion on a weekly schedule in patients (patients) with advanced solid tumours. Proc. Am. Soc. Clin. Oncol. (2001) 20:441 (Abstract).
23. JOHNSON P, O'DONNELL A, PINEL MC et al.: Phase I study of vinflunine given as a 10-minute infusion on days 1 and 8 every 3 weeks in patients with solid malignancies. Proc. Am. Soc. Clin. Oncol. (2001) 20:2100 (Abstract 88b).
24. VERMORKEN JB, STUPP R, NGUYEN L et al.: Phase I study of i.v. vinflunine given on a weekly schedule in previously untreated patients with advanced solid tumours. Proc. Am. Soc. Clin. Oncol. (2003) 22:221 (Abstract 887).
25. BUI B, THEODORE C, CULINE S et al.: Preliminary results of a Phase II study testing intravenous (IV) vinflunine (VFL) as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder. Proc. Am. Soc. Clin. Oncol. (2003) 22:391 (Abstract 1571).
26. CULINE S, THEODORE C, DESANTIS M et al.: A Phase II study testing intravenous (IV) vinflunine as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder. Eur. J. Oncol. (2003) 5:844 (Abstract).
27. WORLD HEALTH ORGANIZATION: WHO handbook for reporting results of cancer treatment. World Health Organization publication, Geneva (1979).
28. FUMOLEAU P, CAMPONE M, VOROBIOF D et al.: Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure. Proc. Am. Soc. Clin. Oncol. (2004) 23:12 (Abstract 542).
29. CAMPONE M, VOROBIOF D, CORTES-FUNES H: Preliminary results of a Phase II study of intravenous vinflunine as second line therapy in patients with metastatic breast cancer after anhracycline-taxane based regimen failure. Breast Cancer Res. Treat. (2003) 82(Suppl. 1S):85 (Abstract 355).
30. BENNOUNA J, TAN EH, O'BRIEN M et al.: Phase II study of IV vinflunine (VFL) as second line treatment of patients (patients) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results. Proc. Am. Soc. Clin. Oncol. (2004) 23:648 (Abstract 7139).
31. TALBOT J, MARGERY G, DABUIS G et al.: Interim results of the Phase II study of vinflunine (VFL) in malignant pleural mesothelioma (MPM). Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 7171).
32. SOUQUET P J, RAMLAU R, SUN X et al.: Vinflunine and cisplatin combination in first line treatment of advanced non-small-cell lung cancer. Final results of a Phase II study. Proceedings of the 11th World Conference on lung cancer. Lung Cancer (2005) 49(2) (Abstract P-574).
33. THERASSE P, ARBRUCK SG, EISENHAUER E et al.: New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. (2000) 92:205-216.
34. LEMARIÉ E, BENNOUNA J, GROSSI F et al.: Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemontsnaive patients (patients): preliminary results of a Phase I and pharmacokinetic study. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 7266).
35. TOURANI JM, PINEL MC, PLANCHARD D et al.: Phase I and pharmacokinetic study of vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonthsnaive patients (patients): final results. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 7271).
36. BARRET JM, ETIEVANT C, HILL BT: In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anti-cancer drugs. Cancer Chemother. Pharmacol. (2000) 45:471-476.
37. ETIEVANT C, BARRET JM, CABROL N et al.: Synergistic effects of the farnesyltransferase inhibitor SCH-66336 and novel vinca alkaloids in A549 non-small cell lung cancer cells in vitro. Clin. Cancer Res. (2003) 9:116 (Abstract A269).
38. KRUCZYNSKI A, RICOME C, ASTRUC J et al.: Markedly augmented in vivo experimental antitumour activity with vinflunine, the most recent vinca alkaloid to show activity in Phase I clinical trials, when combined with DNA damaging anticancer agents. Proc. Am. Assoc. Cancer Res. (2002) 43:268.
39. SHNYDER SD, COOPER PA, GYSELINCK N et al.: Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in transplantable routine adenocarcinoma model. Anticancer Res. (2003) 23:4815-4820.